

Contents

Preface	xi
Acknowledgements	xiii
Contributors' conflict of interest	xv
List of abbreviations	xvii
Chapter 1 Schizophrenia and related psychoses	1
ANTIPSYCHOTIC DRUGS	1
General introduction	1
General principles of prescribing	7
Antipsychotics – minimum effective doses	8
Quick reference for licensed maximum doses	11
Equivalent doses	14
High-dose antipsychotic medication: prescribing and monitoring	17
Combined antipsychotics (antipsychotic polypharmacy)	22
Antipsychotic prophylaxis	28
Negative symptoms	34
Monitoring	40
Relative adverse effects – a rough guide	43
Treatment algorithms for schizophrenia	45
First-generation antipsychotics – place in therapy	49
NICE guidelines for the treatment of schizophrenia	52
Antipsychotic response – to increase the dose, to switch, to add or just wait – what is the right move?	55
Acutely disturbed or violent behaviour	62
Antipsychotic depots/long-acting injections	74
Depot antipsychotics – summary of pharmacokinetics	81
Management of patients on long-term treatment with long-acting injectable antipsychotic medication	83
Aripiprazole long-acting injection	85
Olanzapine long-acting injection	90
Paliperidone palmitate long-acting injection	93
Risperidone long-acting injection	99
Penfluridol weekly	106

Electroconvulsive therapy and psychosis	108
Omega-3 fatty acid (fish oils) in schizophrenia	111
Alternative routes of administration	115
Stopping antipsychotics	119
ANTIPSYCHOTIC ADVERSE EFFECTS	126
Extrapyramidal symptoms	126
Akathisia	131
Treatment of tardive dyskinesia	135
Antipsychotic-induced weight gain	141
Treatment of antipsychotic-induced weight gain	144
Neuroleptic malignant syndrome	150
Catatonia	154
ECG changes – QT prolongation	161
Effects of antipsychotic medications on plasma lipids	169
Diabetes and impaired glucose tolerance	174
Blood pressure changes with antipsychotics	182
Antipsychotic-associated hyponatraemia	186
Hyperprolactinaemia	190
Sexual dysfunction and antipsychotics	195
Pneumonia	204
Switching antipsychotics	207
Venous thromboembolism	211
REFRACTORY SCHIZOPHRENIA AND CLOZAPINE	214
Clozapine initiation schedules	214
Intramuscular clozapine	219
Optimising clozapine treatment	220
Alternatives to clozapine	226
Restarting clozapine after a break in treatment	234
Initiation of clozapine in the community	236
CLOZAPINE ADVERSE EFFECTS	241
Clozapine: common adverse effects	241
Clozapine: uncommon or unusual adverse effects	245
Clozapine: serious haematological adverse effects	251
Clozapine: serious cardiovascular adverse effects	253
Clozapine-induced hypersalivation	258
Clozapine-induced gastrointestinal hypomotility	263
Clozapine, neutropenia and lithium	267
Clozapine and chemotherapy	273
Genetic testing for clozapine treatment	275
Chapter 2 Bipolar disorder	279
Lithium	279
Valproate	289
Carbamazepine	295
Antipsychotic drugs in bipolar disorder	300
Antipsychotic long-acting injections in bipolar disorder	305

Physical monitoring for people with bipolar disorder	308
Treatment of acute mania or hypomania	310
Rapid-cycling bipolar affective disorder	316
Bipolar depression	319
Prophylaxis in bipolar disorder	326
Stopping lithium and mood stabilisers	331
Chapter 3 Depression and anxiety disorders	335
Introduction to depression	335
Antidepressants – general overview	337
Recognised minimum effective doses of antidepressants	342
Drug treatment of depression	344
Management of treatment-resistant depression – commonly used treatments	348
Management of treatment-resistant depression – other well-supported treatments	351
Treatment-resistant depression – other reported treatments	353
Ketamine	357
Psychotic depression	362
Switching antidepressants	366
Antidepressant withdrawal symptoms	373
Stopping antidepressants	378
Electroconvulsive therapy and psychotropic drugs	384
Psychostimulants in depression	388
Post-stroke depression	393
Antidepressant prophylaxis	397
Drug interactions with antidepressants	401
Cardiac effects of antidepressants – summary	406
Antidepressant-induced arrhythmia	411
Antidepressant-induced hyponatraemia	416
Antidepressants and hyperprolactinaemia	420
Antidepressants and diabetes mellitus	423
Antidepressants and sexual dysfunction	426
SSRIs and bleeding	432
St John's wort	440
Antidepressants: relative adverse effects – a rough guide	444
Anxiety spectrum disorders	446
Benzodiazepines in the treatment of psychiatric disorders	460
Benzodiazepines, z-drugs and gabapentinoids: dependence, withdrawal effects and discontinuation	464
Benzodiazepines and disinhibition	471
Premenstrual syndrome	474
Chapter 4 Addictions and substance misuse	477
Introduction	477
Alcohol dependence	479
Opioid dependence	498

Nicotine and smoking cessation	523
Stimulant use disorder (SUD)	532
GHB and GBL dependence	537
Benzodiazepine misuse	540
Drug-induced excited state	543
Interactions between illicit drugs and prescribed psychotropic drugs	545
Drugs of misuse – a summary	549
Substance misuse in pregnancy	554
Gambling disorder	560
Chapter 5 Prescribing in children and adolescents	561
Principles of prescribing practice in childhood and adolescence	561
Depression in children and adolescents	566
Bipolar disorder in children and adolescents	573
Psychosis in children and adolescents	580
Anxiety disorders in children and adolescents	582
Obsessive compulsive disorder (OCD) and body dysmorphic disorder (BDD) in children and adolescents	587
Post-traumatic stress disorder (PTSD) in children and adolescents	595
Attention deficit hyperactivity disorder (ADHD) in children and adolescents	597
Autism spectrum disorder (ASD) in children and adolescents	605
Tics and Tourette's syndrome in children and adolescents	614
Melatonin in the treatment of insomnia in children and adolescents	620
Rapid tranquillisation (RT) in children and adolescents	623
Doses of commonly used psychotropic drugs in children and adolescents	626
Chapter 6 Prescribing in older people	627
General principles in prescribing in older adults	627
Dementia	630
Safer prescribing for physical conditions in dementia	654
Management of behavioural and psychological symptoms of dementia (BPSD)	667
Management of inappropriate sexual behaviour in older adults	680
Depression in older adults	688
Covert administration of medicines within food and drink	694
A guide to medication doses of commonly used psychotropics in older adults	700
Chapter 7 Prescribing in pregnancy and breastfeeding	713
Drug choice in pregnancy	713
Drug choice in breastfeeding	734
Chapter 8 Prescribing in hepatic and renal impairment	753
Hepatic impairment	753
Renal impairment	766
Chapter 9 Drug treatment of other psychiatric conditions	787
Borderline personality disorder (BPD)	787
Eating disorders	792
Attention deficit hyperactivity disorder (ADHD) in adults	798

Chapter 10	Drug treatment of psychiatric symptoms occurring in the context of other conditions	803
	Prescribing in human immunodeficiency virus (HIV)	803
	Epilepsy	811
	22q11.2 deletion syndrome	820
	Learning disabilities	824
	Huntington's disease	830
	Multiple sclerosis	835
	Parkinson's disease	840
	Atrial fibrillation	845
	Bariatric surgery	849
	Menopause	857
Chapter 11	Pharmacokinetics	865
	Plasma level monitoring of psychotropic drugs	865
	Interpreting postmortem blood concentrations	879
	Acting on clozapine plasma concentration results	881
	Psychotropic drugs and cytochrome (CYP) function	883
	Smoking and psychotropic drugs	892
	Drug interactions with alcohol	895
Chapter 12	Other substances	901
	Caffeine	901
	Nicotine	908
Chapter 13	Psychotropic drugs in special conditions	913
	Psychotropics in overdose	913
	Driving and psychotropic medicines	921
Chapter 14	Prescribing psychotropics	927
	Working towards adherence	927
	Restarting psychotropic medications after a period of non-compliance	937
	Relational aspects of prescribing practice	939
	Prescribing drugs outside their licensed indications ('off-label' prescribing)	945
	The Mental Health Act in England and Wales	949
	Site of administration of intramuscular injections	954
Chapter 15	Miscellany	959
	Biochemical and haematological effects of psychotropics	959
	Summary of psychiatric adverse effects of non-psychotropics	969
	Index	975

